By: T. Vermassen PhD, A. Decruyenaere MD, S. Rottey MD, PhD, D. De Maeseneer MD
The 2022 ASCO Annual Meeting again offered a variety of advancements in the treatment of genitourinary cancers. In this summary, some of the highlights in the field of renal, bladder and prostate cancer will be discussed, with a particular focus on studies with a potential impact on clinical practice.
(Belg J Med Oncol 2022;16(5):214–22)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
